Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer

Sun Yat-sen University

Status: Enrolling

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT03260192

LQBC020

Details and patient eligibility

About

Investigators aim to investigate whether circulating tumor DNA is a sensitive marker to evaluate patients' response to neoadjuvant chemotherapy

Full description

Neoadjuvant chemotherapy(NAC) is traditionally for locally advanced disease, converting an inoperable to a resectable tumor.In recent years, it has become an option for patients of lower tumor stage to increase the possibility of breast conserving therapy. An effective method to monitor the response to NAC is important.

Enrollment: 150 estimated patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female patients undergoing NAC
• Age: 18-70 yrs
• Any menopausal status
• Any hormal receptor status

Exclusion criteria

• Metastasis discovered during NAC
• Lost more than 2 blood samples during NAC and surgery